We are in the midst of a heart failure pandemic. There have been advances in medical and device therapy for patients with heart failure and reduced left ventricular ejection fraction.  In vitro diagnostic testing has been important in establishing prognosis as well as a guide to management.  Natriuretic Peptides are currently used in diagnosis, prognosis, screening, and response to treatment for patients with heart failure. Galectin-3 is another blood biomarker of heart failure. Its concentrations are prognostic for heart failure hospitalization and death.  Levels of natriuretic peptides and galectin-3 are complementary in clinical practice.

After this webinar you will be able to;-

• Describe the key challenges of Heart Failure
• Discuss the differences between natriuretic peptides BNP and NT-proBNP for the diagnosis, stratification and management of Heart Failure
• Understand the clinical utility and additive effect of Galectin-3 with natriuretic peptides for prognosis of Heart Failure